The new Bio- and MedTech Business programme will take place from 8 to 13 November 2026 in Ascona (Monte Verità). The programme includes a BioTech and a MedTech track for sector-specific training and will be combined with an Investor Forum.
We would like to warmly thank Piero Martinoli, Chairman of the Advisory Board, for initiating and supporting CASE BioMed. Many of the entrepreneurs who have been trained have sold their companies and helped to strengthen the innovative power of our economy.
This textbook allows our students a better preparation and a retrospective review of the program week
Proteomedix, a spin-off of ETHZ and founded by the CASE BioMed alumni R. Schiess and C. Brühlmann, has been acquired by US-based, NASDAQ-listed Blue Water Biotech Inc. Proteomedix shareholders received a mix of common shares and preferred shares.
The completeness of the program, the specificity of all the modules and the level of the invited lecturers and seminars make the BioBusiness program a must have for entrepreneurs in Life Sciences in Switzerland.
